TR27402A - Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri. - Google Patents

Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.

Info

Publication number: TR27402A
Authority: TR; Turkey
Prior art keywords: coated; percarbonate particles; sodium percarbonate; pct; detergent
Prior art date: 1993-04-10

Application number

TR00294/94A

Other languages

English (en)

Original Assignee

Degussa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-10

Filing date

1994-04-04

Publication date

1995-02-28

1994-04-04 Application filed by Degussa filed Critical Degussa

1995-02-28 Publication of TR27402A publication Critical patent/TR27402A/tr

Classifications

- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C01B15/106—Stabilisation of the solid compounds, subsequent to the preparation or to the crystallisation, by additives or by coating
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/39—Organic or inorganic per-compounds
- C11D3/3942—Inorganic per-compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Wood Science & Technology (AREA)
Detergent Compositions (AREA)

TR00294/94A 1993-04-10 1994-04-04 Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri. TR27402A (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4311944A DE4311944A1 (de)	1993-04-10	1993-04-10	Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen

Publications (1)

Publication Number	Publication Date
TR27402A true TR27402A (tr)	1995-02-28

Family

ID=6485306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR00294/94A TR27402A (tr)	1993-04-10	1994-04-04	Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.

Country Status (17)

Country	Link
US (1)	US5658873A (tr)
EP (1)	EP0693039B1 (tr)
JP (1)	JP3599737B2 (tr)
KR (1)	KR100308473B1 (tr)
CN (1)	CN1120832A (tr)
AT (1)	ATE156096T1 (tr)
AU (1)	AU6207894A (tr)
CA (1)	CA2159991A1 (tr)
CZ (1)	CZ249895A3 (tr)
DE (2)	DE4311944A1 (tr)
ES (1)	ES2106515T3 (tr)
FI (1)	FI954808A0 (tr)
PL (1)	PL173925B1 (tr)
SI (1)	SI9400166A (tr)
TR (1)	TR27402A (tr)
TW (1)	TW265320B (tr)
WO (1)	WO1994024044A1 (tr)

Families Citing this family (603)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
DE69433036T2 (de)	1993-09-03	2004-05-27	Isis Pharmaceuticals, Inc., Carlsbad	Aminoderivatisierte nukleoside und oligonukleoside
DE4439069A1 (de) *	1994-11-02	1996-05-09	Degussa	Percarbonathaltige Wasch-, Bleich- und Reinigungsmittelzusammensetzung
DE19629381A1 (de) *	1996-07-20	1998-01-22	Eilenburger Elektrolyse & Umwelttechnik Gmbh	Granulierter Aktivsauerstoffträger
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
DE19544293C2 (de) *	1995-11-28	1998-01-29	Degussa	Umhüllte Natriumpercarbonatpartikel und deren Verwendung
DE19600018A1 (de)	1996-01-03	1997-07-10	Henkel Kgaa	Waschmittel mit bestimmten oxidierten Oligosacchariden
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
CA2294988C (en)	1997-07-01	2015-11-24	Isis Pharmaceuticals Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
FR2768140B1 (fr) *	1997-09-05	1999-10-08	Atochem Elf Sa	Solution sursaturee stable de perborate de sodium et son application dans la fabrication des particules de percarbonate de sodium stabilisees
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
CA2329252A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for topical delivery of oligonucleotides
CA2329130A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
WO2000017309A1 (en) *	1998-09-23	2000-03-30	The Procter & Gamble Company	Coated perborate bleach and compositions containing the same
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US7668658B2 (en)	1999-10-13	2010-02-23	Sequenom, Inc.	Methods for generating databases and databases for identifying polymorphic genetic markers
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
EP1127840A1 (en) *	2000-02-21	2001-08-29	SOLVAY & Cie (Société Anonyme)	Process for preparing coated alkali metal percarbonate, coated alkaki metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it
JP2003530841A (ja) *	2000-04-13	2003-10-21	トーマスエヌ．ワイト，	治療的化合物および方法
KR100366556B1 (ko)	2000-04-26	2003-01-09	동양화학공업주식회사	세제용 입상 코티드 과탄산나트륨과 이의 제조방법
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en)	2000-10-12	2007-07-05	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US6573051B2 (en) *	2001-03-09	2003-06-03	Molecular Staging, Inc.	Open circle probes with intramolecular stem structures
ES2328796T3 (es)	2001-03-14	2009-11-18	Myriad Genetics, Inc.	Interaccion tsg101-gag y uso de la misma.
KR100788092B1 (ko)	2001-06-20	2007-12-21	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
WO2003000707A2 (en)	2001-06-21	2003-01-03	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
EP2143438B1 (en)	2001-09-18	2011-07-13	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumors
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ577565A (en)	2001-10-09	2010-10-29	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expressions
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
EP2067472A1 (en)	2002-01-02	2009-06-10	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7553619B2 (en)	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
AU2003230874A1 (en)	2002-04-16	2003-11-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2003093296A2 (en)	2002-05-03	2003-11-13	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040092470A1 (en) *	2002-06-18	2004-05-13	Leonard Sherry A.	Dry powder oligonucleotide formualtion, preparation and its uses
WO2004013160A2 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
BR0314236A (pt)	2002-09-13	2005-08-09	Replicor Inc	Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EP2322535A3 (en)	2002-09-20	2011-09-28	Yale University	Riboswitches, methods for their use, and compositions for use with riboswitches
EP1549767A4 (en)	2002-09-26	2006-06-07	Amgen Inc	MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
AU2003290598A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
WO2004044138A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2336318B1 (en)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
PT2336318E (pt)	2002-11-13	2013-06-12	Genzyme Corp	Modulação anti-sentido da expressão de apolipoproteína b
EP1572971B1 (en)	2002-11-15	2009-09-30	Morphotek Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
WO2004045520A2 (en)	2002-11-15	2004-06-03	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
US7557092B2 (en)	2002-11-21	2009-07-07	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121338A1 (en) *	2002-12-19	2004-06-24	Alsmadi Osama A.	Real-time detection of rolling circle amplification products
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
DE10320197A1 (de) *	2002-12-20	2004-07-08	Degussa Ag	Umhüllte Persauerstoffverbindungen mit kontrollierter Freisetzung, Verfahren zu ihrer Herstellung und ihrer Verwendung
JP4886298B2 (ja)	2002-12-20	2012-02-29	キアゲンゲゼルシャフトミットベシュレンクテルハフツング	核酸増幅
US6977153B2 (en)	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US7468356B2 (en)	2003-02-11	2008-12-23	Antisense Therapeutics Ltd.	Modulation of insulin like growth factor I receptor expression
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
CA2540692C (en)	2003-06-02	2013-05-28	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
US7541344B2 (en)	2003-06-03	2009-06-02	Eli Lilly And Company	Modulation of survivin expression
US7786290B2 (en)	2003-06-13	2010-08-31	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
EP1644475A4 (en)	2003-06-20	2009-06-03	Isis Pharmaceuticals Inc	DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
EA009670B1 (ru)	2003-09-18	2008-02-28	Ай Эс Ай Эс ФАРМАСЬЮТИКАЛЗ, ИНК.	МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
EP1677822B1 (en)	2003-09-18	2014-04-23	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
DK2161283T3 (da)	2003-11-17	2014-09-01	Genentech Inc	SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
JP2007520222A (ja)	2004-01-20	2007-07-26	アイシスファーマシューティカルズインコーポレイテッド	グルココルチコイドレセプター発現の調節
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en)	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
EP1737878A2 (en)	2004-04-05	2007-01-03	Alnylam Pharmaceuticals Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US7674778B2 (en)	2004-04-30	2010-03-09	Alnylam Pharmaceuticals	Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
JP2008500064A (ja)	2004-05-21	2008-01-10	ザユーエービーリサーチファウンデーション	可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006032144A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
AU2005327506B2 (en)	2004-10-20	2010-07-08	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha4 expression
US20060105937A1 (en) *	2004-11-15	2006-05-18	Melani Hardt Duran	Aqueous cleaning composition
WO2006063031A2 (en) *	2004-12-06	2006-06-15	Haplomics	Allelic variants of human factor viii
EP1869076A2 (en)	2005-03-10	2007-12-26	Genentech, Inc.	Methods and compositions for modulating vascular integrity
US7476733B2 (en)	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
GB0508622D0 (en) *	2005-04-28	2005-06-08	Probe Ind Ltd	Method for treating effluent
JP5329949B2 (ja)	2005-05-31	2013-10-30	エコーレポリテクニークフェデラーレデローザンヌ	遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
EP1904111A4 (en)	2005-06-03	2009-08-19	Univ Johns Hopkins	COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
EP1929012B1 (en)	2005-08-11	2010-10-06	Synthetic Genomics, Inc.	Method for in vitro recombination
EP1915461B1 (en)	2005-08-17	2018-08-01	Dx4U GmbH	Composition and method for determination of ck19 expression
EP1931780B1 (en)	2005-08-29	2016-01-06	Regulus Therapeutics Inc.	Antisense compounds having enhanced anti-microrna activity
CA2620856C (en)	2005-08-29	2017-11-28	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2189522A1 (en)	2005-10-14	2010-05-26	MUSC Foundation For Research Development	Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP1941059A4 (en) *	2005-10-28	2010-11-03	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE
WO2007056326A2 (en) *	2005-11-04	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of nav1.8 gene
US20100069461A1 (en)	2005-11-09	2010-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
JP2009516710A (ja)	2005-11-21	2009-04-23	アイシスファーマシューティカルズ，インコーポレーテッド	ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
US8313901B2 (en) *	2005-12-21	2012-11-20	Yale University	Methods and compositions related to the modulation of riboswitches
CN101437933B (zh)	2005-12-28	2013-11-06	斯克里普斯研究所	作为药物靶标的天然反义和非编码的rna转录物
US20070299027A1 (en)	2006-01-26	2007-12-27	Gene Hung	Compositions and their uses directed to huntingtin
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
WO2007090073A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
CN102908630B (zh)	2006-01-27	2014-11-19	Isis制药公司	6-修饰的双环核酸类似物
CA2873833A1 (en)	2006-03-31	2007-10-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 gene
BRPI0711182A2 (pt)	2006-05-03	2011-08-23	Baltic Technology Dev	agentes anti-sentido combinando base fortemente ligada-oligonucleotìdeo modificado e nuclease artificial
ES2386578T3 (es) *	2006-05-05	2012-08-23	Isis Pharmaceuticals, Inc.	Compuestos y procedimientos para modular la expresión de PCSK9
EP2505649A1 (en)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of GCGR
US7547684B2 (en) *	2006-05-11	2009-06-16	Isis Pharmaceuticals, Inc.	5′-modified bicyclic nucleic acid analogs
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
JP2009537153A (ja)	2006-05-19	2009-10-29	アルニラムファーマシューティカルズ，インコーポレイテッド	ＡｈａのＲＮＡｉ調節およびその治療上の使用
US7888498B2 (en)	2006-05-22	2011-02-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of IKK-B gene
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
WO2008017081A1 (en) *	2006-08-04	2008-02-07	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of jnk proteins
WO2008033866A2 (en) *	2006-09-11	2008-03-20	Yale University	Methods and compositions for the use of lysine riboswitches
US7947487B2 (en)	2006-10-05	2011-05-24	Massachusetts Institute Of Technology	Multifunctional encoded particles for high-throughput analysis
DK2410054T4 (da)	2006-10-18	2020-02-10	Ionis Pharmaceuticals Inc	Antisenseforbindelser
US8999317B2 (en)	2006-11-01	2015-04-07	University Of Rochester	Methods and compositions related to the structure and function of APOBEC3G
US8084437B2 (en) *	2006-11-27	2011-12-27	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
EP2097448A4 (en)	2006-12-22	2010-07-21	Univ Utah Res Found	PROCEDURE FOR THE EVIDENCE OF EYE DISEASES AND SUFFERINGS AND THEIR TREATMENT
EP2121987B1 (en)	2007-02-09	2012-06-13	Northwestern University	Particles for detecting intracellular targets
MX2009009127A (es) *	2007-02-27	2009-10-19	Univ Northwestern	Unión de moléculas a nanopartículas.
EP2471925A1 (en)	2007-03-22	2012-07-04	Yale University	Methods and compositions related to riboswitches that control alternative splicing
WO2008121604A2 (en)	2007-03-29	2008-10-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the ebola
AU2008251381B2 (en)	2007-05-11	2014-10-30	The Johns Hopkins University	Biomarkers for melanoma
KR20100017893A (ko) *	2007-05-29	2010-02-16	예일 유니버시티	택일적 스플라이싱 및 ｒｎａ 프로세싱을 조절하는 리보스위치와 관련된 방법 및 조성물
EP2426218A1 (en)	2007-05-29	2012-03-07	Yale University	Riboswitches and methods and compositions for use of and with riboswitches
WO2008150729A2 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2160464T3 (da)	2007-05-30	2014-08-04	Univ Northwestern	Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
ATE538127T1 (de) *	2007-07-05	2012-01-15	Isis Pharmaceuticals Inc	6-disubstituierte bicyclische nukleinsäureanaloga
AU2008286771B2 (en)	2007-08-15	2013-08-15	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US9422363B2 (en)	2007-08-28	2016-08-23	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032702A2 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
WO2009067243A2 (en)	2007-11-20	2009-05-28	Isis Pharmaceuticals Inc.	Modulation of cd40 expression
EP2848688A1 (en)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor VII gene
EP3100718B1 (en)	2008-01-02	2019-11-27	Arbutus Biopharma Corporation	Improved compositions and methods for the delivery of nucleic acids
CN102014932B (zh)	2008-03-05	2015-11-25	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因表达的组合物和方法
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
DK2285819T3 (da) *	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
ES2686708T3 (es)	2008-04-18	2018-10-19	Baxter International Inc.	Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
CN101270232B (zh) *	2008-04-22	2011-04-20	浙江时代金科过氧化物有限公司	一种颗粒型包膜过碳酸钠的制备方法
US20090274696A1 (en) *	2008-04-29	2009-11-05	Wyeth	Methods for treating inflammation
US8222221B2 (en)	2008-06-04	2012-07-17	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small RNA targeting of gene promoters
JP2011529686A (ja)	2008-07-29	2011-12-15	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	ポリグルタミンタンパク質発現の選択的阻害
WO2010027832A1 (en)	2008-08-25	2010-03-11	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to ctgf
US8252762B2 (en)	2008-08-25	2012-08-28	Excaliard Pharmaceuticals, Inc.	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3208337A1 (en)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Compositions for combined inhibition of mutant egfr and il-6 expression
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
US20100075883A1 (en) *	2008-09-24	2010-03-25	Ecolab Inc.	Granular cleaning and disinfecting composition
EP3584320A1 (en)	2008-09-25	2019-12-25	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
EP2350043B9 (en)	2008-10-09	2014-08-20	TEKMIRA Pharmaceuticals Corporation	Improved amino lipids and methods for the delivery of nucleic acids
CA3222620A1 (en)	2008-10-20	2010-04-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin
EP2447274B1 (en)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CA2744207C (en)	2008-11-24	2019-05-28	Northwestern University	Polyvalent rna-nanoparticle compositions
CA2746001C (en)	2008-12-04	2020-03-31	Joseph Collard	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
RU2746478C2 (ru)	2008-12-04	2021-04-14	КьюРНА, Инк.	Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
AU2009324534B2 (en)	2008-12-10	2015-07-30	Alnylam Pharmaceuticals, Inc.	GNAQ targeted dsRNA compositions and methods for inhibiting expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
US20120101148A1 (en)	2009-01-29	2012-04-26	Alnylam Pharmaceuticals, Inc.	lipid formulation
WO2010091308A2 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20110319476A1 (en)	2009-02-12	2011-12-29	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
EP2396038B1 (en)	2009-02-12	2015-10-21	CuRNA, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
JP6250263B2 (ja)	2009-03-04	2017-12-20	クルナ・インコーポレーテッド	サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
CA2754043A1 (en)	2009-03-12	2010-09-16	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP2408919B1 (en)	2009-03-16	2017-10-18	CuRNA, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
ES2627763T3 (es)	2009-03-17	2017-07-31	Curna, Inc.	Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
WO2010120420A1 (en)	2009-04-15	2010-10-21	Northwestern University	Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (en)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Innate immune suppression enables repeated delivery of long rna molecules
EP2421972A2 (en)	2009-04-24	2012-02-29	The Board of Regents of The University of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010127195A2 (en)	2009-05-01	2010-11-04	Curna, Inc.	Antisense oligonucleotides of hemoglobins
WO2010129687A1 (en)	2009-05-05	2010-11-11	Alnylam Pharmaceuticals, Inc	Methods of delivering oligonucleotides to immune cells
KR20240015723A (ko)	2009-05-05	2024-02-05	알닐람 파마슈티칼스 인코포레이티드	지질 조성물
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010132665A1 (en)	2009-05-15	2010-11-18	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (ko)	2009-05-22	2017-02-08	큐알엔에이, 인크.	전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
ES2618576T3 (es)	2009-05-28	2017-06-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
CA2764609C (en)	2009-06-10	2018-10-02	Alnylam Pharmaceuticals, Inc.	Improved cationic lipid of formula i
CA2765509C (en)	2009-06-16	2021-08-17	Joseph Collard	Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN115227710A (zh)	2009-06-17	2022-10-25	冷泉港实验室	用于在对象中调节smn2剪接的组合物和方法
KR101807323B1 (ko)	2009-06-24	2017-12-08	큐알엔에이, 인크.	Ｔｎｆｒ2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(ｔｎｆｒ2) 관련된 질환의 치료
US8921330B2 (en)	2009-06-26	2014-12-30	Curna, Inc.	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011017516A2 (en)	2009-08-05	2011-02-10	Curna, Inc.	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011020023A2 (en)	2009-08-14	2011-02-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
WO2011031482A2 (en)	2009-08-25	2011-03-17	Curna, Inc.	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2599076T3 (es)	2009-09-02	2017-01-31	Genentech, Inc.	Smoothened mutante y métodos de utilización del mismo
WO2011050194A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US20110129832A1 (en) *	2009-10-27	2011-06-02	Swift Biosciences, Inc.	Polynucleotide Primers and Probes
KR20120136345A (ko)	2009-10-30	2012-12-18	노오쓰웨스턴 유니버시티	주형화된 나노컨쥬게이트
US20110110860A1 (en)	2009-11-02	2011-05-12	The Board Of Regents Of The University Of Texas System	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
WO2011056215A1 (en)	2009-11-03	2011-05-12	Landers James P	Versatile, visible method for detecting polymeric analytes
JP2013511285A (ja)	2009-11-23	2013-04-04	スイフト・バイオサイエンシズ・インコーポレイテツド	一本鎖標的分子を伸長させるデバイス
CN102741294A (zh)	2009-11-30	2012-10-17	霍夫曼-拉罗奇有限公司	治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
ES2661813T3 (es)	2009-12-16	2018-04-04	Curna, Inc.	Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
US9068183B2 (en)	2009-12-23	2015-06-30	Curna, Inc.	Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
JP5982288B2 (ja)	2009-12-29	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
EP2519633B1 (en)	2009-12-29	2017-10-25	CuRNA, Inc.	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101878501B1 (ko)	2010-01-04	2018-08-07	큐알엔에이, 인크.	인터페론 조절 인자 8 (ｉｒｆ8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (ｉｒｆ8) 관련된 질환의 치료
WO2011085066A2 (en)	2010-01-06	2011-07-14	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
CN102803493B (zh)	2010-01-11	2018-07-31	库尔纳公司	通过抑制性激素结合球蛋白(shbg)的天然反义转录物而治疗shbg相关疾病
EP2524042A2 (en)	2010-01-12	2012-11-21	Yale University	Structured rna motifs and compounds and methods for their use
BR112012017483A2 (pt) *	2010-01-14	2019-09-24	Haplomics Inc	previsão e redução de aloimunogenicidade de terapêuticos de proteína
KR101853510B1 (ko)	2010-01-25	2018-06-20	큐알엔에이, 인크.	Ｒｎａｓｅｈ1에 대한 천연 안티센스 전사체의 억제에 의한 ｒｎａｓｅｈ1과 관련된 질환의 치료
US9574191B2 (en)	2010-02-03	2017-02-21	The Board Of Regents Of The University Of Texas System	Selective inhibition of polyglutamine protein expression
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
CA2790506A1 (en)	2010-02-22	2011-08-25	Curna, Inc.	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011106297A2 (en)	2010-02-23	2011-09-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
ES2893199T3 (es)	2010-03-29	2022-02-08	Alnylam Pharmaceuticals Inc	Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
US8507663B2 (en)	2010-04-06	2013-08-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
EP2556160A4 (en)	2010-04-09	2013-08-21	Curna Inc	TREATMENT OF ILLNESSES ASSOCIATED WITH FIBROBLASTIC GROWTH FACTOR 21 (FGF21) BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPT AGAINST FGF21
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
KR20180026798A (ko)	2010-04-29	2018-03-13	아이오니스 파마수티컬즈, 인코포레이티드	트랜스티레틴 발현의 조절
AU2011248354A1 (en)	2010-05-03	2012-11-08	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
KR101857090B1 (ko)	2010-05-26	2018-06-26	큐알엔에이, 인크.	무조(無調)의 동소체 1 (atoh1)에 대한 자연 안티센스 전사체의 저해에 의한 atoh1 관련된 질환의 치료
WO2011153323A2 (en)	2010-06-02	2011-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156432A2 (en)	2010-06-07	2011-12-15	Firefly Bioworks, Inc.	Scanning multifunctional particles
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
RU2611190C2 (ru)	2010-07-14	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
US20130143955A1 (en)	2010-08-09	2013-06-06	Yale University	Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
EP2630241B1 (en)	2010-10-22	2018-10-17	CuRNA, Inc.	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
CN103201387B (zh)	2010-10-27	2018-02-02	库尔纳公司	通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
US9339513B2 (en)	2010-11-09	2016-05-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
RU2608493C2 (ru)	2010-11-23	2017-01-18	Курна, Инк.	Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
PT2670411T (pt)	2011-02-02	2019-06-18	Excaliard Pharmaceuticals Inc	Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
EP2670404B1 (en)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin modulators as virus production modulators
WO2012106591A1 (en)	2011-02-03	2012-08-09	Mirna Therapeutics, Inc.	Synthetic mimics of mir-34
JP2014506789A (ja)	2011-02-03	2014-03-20	マーナセラピューティクスインコーポレイテッド	ｍｉＲ−１２４の合成模倣体
WO2012109395A1 (en)	2011-02-08	2012-08-16	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
CN103813810B (zh)	2011-03-29	2021-08-03	阿尔尼拉姆医药品有限公司	用于抑制tmprss6基因表达的组合物和方法
EP3460064B8 (en)	2011-04-03	2024-03-20	The General Hospital Corporation d/b/a Massachusetts General Hospital	Efficient protein expression in vivo using modified rna (mod-rna)
US20140186844A1 (en)	2011-04-26	2014-07-03	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
US9593330B2 (en)	2011-06-09	2017-03-14	Curna, Inc.	Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
KR102540778B1 (ko)	2011-06-21	2023-06-07	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
CN120555426A (zh)	2011-06-21	2025-08-29	阿尔尼拉姆医药品有限公司	血管生成素样3（ANGPTL3）iRNA组合物及其使用方法
US9068184B2 (en)	2011-06-21	2015-06-30	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of protein C (PROC) genes
WO2012178033A2 (en)	2011-06-23	2012-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
EP3556859B1 (en)	2011-08-11	2021-04-07	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
CA2847698C (en)	2011-09-14	2020-09-01	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
HUE039133T2 (hu)	2011-10-14	2018-12-28	Hoffmann La Roche	Anti-HtrA1 antitestek és felhasználási módszerek
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
PL2791160T3 (pl)	2011-12-16	2022-06-20	Modernatx, Inc.	Kompozycje zmodyfikowanego mrna
CA2860731C (en)	2012-01-10	2023-02-28	M. Mahmood Hussain	Method of treating hyperlipidemia and atherosclerosis with mir-30c
EP2825672B1 (en)	2012-03-13	2019-02-13	Swift Biosciences, Inc.	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
ES2694592T3 (es)	2012-03-15	2018-12-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
CA2907072A1 (en)	2012-03-16	2013-09-19	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of dmpk
HK1206779A1 (en)	2012-04-02	2016-01-15	Modernatx, Inc.	Modified polynucleotides for the production of nuclear proteins
AU2013243949A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
US9993522B2 (en)	2012-09-18	2018-06-12	Uti Limited Partnership	Treatment of pain by inhibition of USP5 de-ubiquitinase
US9695418B2 (en)	2012-10-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
CA2887702C (en)	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
ES2949394T3 (es)	2012-11-05	2023-09-28	Found Medicine Inc	Moléculas de fusión novedosas y usos de las mismas
DK2922554T3 (en)	2012-11-26	2022-05-23	Modernatx Inc	Terminalt modificeret rna
US10272163B2 (en)	2012-12-07	2019-04-30	The Regents Of The University Of California	Factor VIII mutation repair and tolerance induction
AU2013374345A1 (en)	2013-01-17	2015-08-06	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
US10398661B2 (en)	2013-02-28	2019-09-03	The Board Of Regents Of The University Of Texas System	Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
EP2968391A1 (en)	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
EP2971010B1 (en)	2013-03-14	2020-06-10	ModernaTX, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN120574828A (zh)	2013-03-14	2025-09-02	阿尔尼拉姆医药品有限公司	补体组分C5 iRNA组合物及其使用方法
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
CN115261411A (zh)	2013-04-04	2022-11-01	哈佛学院校长同事会	利用CRISPR/Cas系统的基因组编辑的治疗性用途
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
SG10202103166XA (en)	2013-05-22	2021-04-29	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
PL2999785T3 (pl)	2013-05-22	2018-09-28	Alnylam Pharmaceuticals, Inc.	Kompozycje iRNA Serpina1 i sposoby ich zastosowania
EP3004396B1 (en)	2013-06-06	2019-10-16	The General Hospital Corporation	Compositions for the treatment of cancer
DK3007704T3 (da)	2013-06-13	2021-03-29	Antisense Therapeutics Ltd	Kombinationsterapi til akromegali
PT3019619T (pt)	2013-07-11	2021-11-11	Modernatx Inc	Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
HRP20200250T1 (hr)	2013-08-08	2020-05-29	The Scripps Research Institute	Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida
EP3041938A1 (en)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Circular polynucleotides
US20160194625A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Chimeric polynucleotides
CA2925107A1 (en)	2013-10-02	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3052628B1 (en)	2013-10-04	2020-02-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene
US10584387B2 (en)	2013-10-09	2020-03-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma
CA2928779A1 (en)	2013-10-21	2015-04-30	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
CN112107693B (zh)	2013-12-03	2023-05-26	西北大学	脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
SG11201604692UA (en)	2013-12-12	2016-07-28	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
JP6599334B2 (ja)	2013-12-20	2019-10-30	ザジェネラルホスピタルコーポレイション	血中循環腫瘍細胞に関する方法およびアッセイ
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
CN106103718B (zh)	2014-02-11	2021-04-02	阿尔尼拉姆医药品有限公司	己酮糖激酶(KHK)iRNA组合物及其使用方法
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
MA39835A (fr)	2014-04-17	2017-02-22	Biogen Ma Inc	Compositions et procédés de modulation de l'épissage du smn2 chez un patient
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
WO2015179724A1 (en)	2014-05-22	2015-11-26	Alnylam Pharmaceuticals, Inc.	Angiotensinogen (agt) irna compositions and methods of use thereof
JP2017518307A (ja)	2014-06-02	2017-07-06	チルドレンズメディカルセンターコーポレーション	免疫調節のための方法および組成物
US10434064B2 (en)	2014-06-04	2019-10-08	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP6851201B2 (ja)	2014-06-10	2021-03-31	エラスムスユニバーシティメディカルセンターロッテルダムＥｒａｓｍｕｓＵｎｉｖｅｒｓｉｔｙＭｅｄｉｃａｌＣｅｎｔｅｒＲｏｔｔｅｒｄａｍ	ポンペ病の治療に有用なアンチセンスオリゴヌクレオチド
AU2015289583A1 (en)	2014-07-16	2017-02-02	Modernatx, Inc.	Chimeric polynucleotides
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
USRE50320E1 (en)	2014-07-31	2025-03-04	Uab Research Foundation	APOE mimetic peptides and higher potency to clear plasma cholesterol
AU2015305482B2 (en)	2014-08-19	2021-04-01	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10060921B2 (en)	2014-08-29	2018-08-28	Alnylam Pharmaceuticals, Inc.	Methods of treating transthyretin (TTR) mediated amyloidosis
KR20170070022A (ko)	2014-08-29	2017-06-21	칠드런'즈 메디컬 센터 코포레이션	암의 치료를 위한 방법 및 조성물
EP3191591A1 (en)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
EA201790642A1 (ru)	2014-09-18	2017-09-29	Ти Юниверсити Оф Бритиш Коламбиа	Аллель-специфическая терапия для гаплотипов болезни хантингтона
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3207138B1 (en)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3904519A1 (en)	2014-10-30	2021-11-03	Genzyme Corporation	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
CA2967184A1 (en)	2014-11-10	2016-05-19	Glaxosmithkline Intellectual Property (No.2) Limited	Combination long acting compositions and methods for hepatitis c
CR20170191A (es)	2014-11-10	2017-09-29	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones farmacéuticas de acción prolongada para la hepatitis c
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
JP2017535552A (ja)	2014-11-17	2017-11-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US20160145547A1 (en)	2014-11-25	2016-05-26	Milliken & Company	Film-Encased Cleaning Composition
AU2015364508A1 (en)	2014-12-18	2017-07-06	Alnylam Pharmaceuticals, Inc.	ReversirTM compounds
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP2018510621A (ja)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
JP2018510657A (ja)	2015-03-27	2018-04-19	プレジデントアンドフェローズオブハーバードカレッジ	改変ｔ細胞ならびにそれを作製および使用する方法
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
EP3324980B1 (en)	2015-07-17	2021-11-10	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
AU2016315584B2 (en)	2015-09-02	2022-07-14	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
EP3368578B1 (en)	2015-10-30	2021-03-17	H. Hoffnabb-La Roche Ag	Anti-htra1 antibodies and methods of use thereof
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
TWI836281B (zh)	2015-12-07	2024-03-21	美商健贊公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法及組成物
AU2015416656B2 (en)	2015-12-07	2023-02-23	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for Pompe disease
US11761007B2 (en)	2015-12-18	2023-09-19	The Scripps Research Institute	Production of unnatural nucleotides using a CRISPR/Cas9 system
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
WO2017136558A1 (en)	2016-02-04	2017-08-10	Curis, Inc.	Mutant smoothened and methods of using the same
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
US20190218257A1 (en)	2016-06-24	2019-07-18	The Scripps Research Institute	Novel nucleoside triphosphate transporter and uses thereof
CN109844103A (zh)	2016-07-21	2019-06-04	美克斯细胞有限公司	用于修饰基因组dna的方法和组合物
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
TWI788312B (zh)	2016-11-23	2023-01-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
KR20190098181A (ko)	2016-12-16	2019-08-21	알닐람 파마슈티칼스 인코포레이티드	트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
KR102619197B1 (ko)	2017-01-23	2024-01-03	리제너론 파마슈티칼스 인코포레이티드	Hsd17b13 변종 및 이것의 용도
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
WO2018195165A1 (en)	2017-04-18	2018-10-25	Alnylam Pharmaceuticals, Inc.	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
MA49578A (fr)	2017-07-11	2021-04-07	Synthorx Inc	Incorporation de nucléotides non naturels et procédés associés
WO2019014262A1 (en)	2017-07-11	2019-01-17	The Scripps Research Institute	INCORPORATION OF NON-NATURAL NUCLEOTIDES AND METHODS OF IN VIVO USE THEREOF
JP7277432B2 (ja)	2017-07-13	2023-05-19	アルナイラムファーマシューティカルズ，インコーポレイテッド	乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
AU2018314159A1 (en)	2017-07-13	2020-01-30	Northwestern University	General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
IL322312A (en)	2017-08-03	2025-09-01	Synthorx Inc	Cytokine conjugates for the treatment of infectious diseases and cell proliferation
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
US11806360B2 (en)	2017-09-19	2023-11-07	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
AU2018360697A1 (en)	2017-11-01	2020-05-14	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
EP3710587A1 (en)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3714053B1 (en)	2017-11-22	2025-12-31	The University of Chicago	CHEMICALLY DEPENDENT PROBE EVALUATION OF PROTEIN ACTIVITY AND ITS USES
EA202091520A1 (ru)	2017-12-18	2020-10-05	Элнилэм Фармасьютикалз, Инк.	Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
EP3732187A4 (en)	2017-12-29	2021-11-10	The Scripps Research Institute	INNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE
US20190233816A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
CA3091857A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
US12473598B2 (en)	2018-03-28	2025-11-18	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in DNA isolated from exosomes
US20210155959A1 (en)	2018-04-06	2021-05-27	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
CA3106701A1 (en)	2018-08-13	2020-02-20	Alnylam Pharmaceuticals, Inc.	Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
TW202020157A (zh)	2018-08-16	2020-06-01	美商艾爾妮蘭製藥公司	用於抑制lect2基因表現之組合物及方法
CN112912422A (zh)	2018-09-14	2021-06-04	西北大学	用dna编程蛋白质聚合
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
US12258620B2 (en)	2018-09-25	2025-03-25	Co-Diagnostics, Inc.	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
AU2019350765A1 (en)	2018-09-28	2021-05-27	Alnylam Pharmaceuticals, Inc.	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
MA54195A (fr)	2018-11-08	2022-02-16	Synthorx Inc	Conjugués d'interleukine 10 et leurs utilisations
EP3894559A4 (en)	2018-12-03	2023-04-05	Triplet Therapeutics, Inc.	METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
US20210332495A1 (en)	2018-12-06	2021-10-28	Northwestern University	Protein Crystal Engineering Through DNA Hybridization Interactions
LT3897672T (lt)	2018-12-20	2023-11-10	Vir Biotechnology, Inc.	Kombinuota hbv terapija
JP2022515744A (ja)	2018-12-20	2022-02-22	プラクシスプレシジョンメディシンズ，インコーポレイテッド	Ｋｃｎｔ１関連障害の治療のための組成物及び方法
BR112021013956A2 (pt)	2019-01-16	2021-09-21	Genzyme Corporation	Composições de irna de serpinc1 e métodos de uso das mesmas
CA3127689A1 (en)	2019-02-06	2020-08-13	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
AU2020276243B2 (en)	2019-05-13	2025-12-18	Vir Biotechnology, Inc.	Compositions and methods for treating hepatitis B virus (HBV) infection
EP3969052A1 (en)	2019-05-17	2022-03-23	Alnylam Pharmaceuticals Inc.	Oral delivery of oligonucleotides
TW202544247A (zh)	2019-06-14	2025-11-16	美商史基普研究協會	於半合成生物體中複製、轉錄及轉譯之試劑及方法
EP4007812A1 (en)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
KR20220047598A (ko)	2019-08-15	2022-04-18	신톡스, 인크.	Il-2 콘쥬게이트를 사용한 면역 종양학 병용 요법
CA3148135A1 (en)	2019-08-23	2021-03-04	Carolina E. CAFFARO	Il-15 conjugates and uses thereof
JP7805286B2 (ja)	2019-09-03	2026-01-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
CN114746122A (zh)	2019-09-10	2022-07-12	新索思股份有限公司	Il-2缀合物和治疗自身免疫性疾病的使用方法
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4038189A1 (en)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
AU2020369515A1 (en)	2019-10-22	2022-04-21	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
AR120341A1 (es)	2019-11-01	2022-02-09	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
TWI891672B (zh)	2019-11-04	2025-08-01	美商欣爍克斯公司	介白素10接合物及其用途
CA3160329A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
EP4055165A1 (en)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
US20230056569A1 (en)	2019-11-22	2023-02-23	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
TWI897902B (zh)	2019-12-13	2025-09-21	美商阿尼拉製藥公司	人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
US12503695B2 (en)	2020-01-27	2025-12-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en)	2020-02-10	2022-10-01	Alnylam Pharmaceuticals Inc	Preparations and methods for silencing vegf-a expression
KR20220143106A (ko)	2020-02-18	2022-10-24	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
IL296109A (en)	2020-03-06	2022-11-01	Alnylam Pharmaceuticals Inc	Ketohexokinase (khk) irna compositions and methods of use thereof
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
JP2023519274A (ja)	2020-03-26	2023-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	コロナウイルスｉＲＮＡ組成物およびその使用方法
WO2021202443A2 (en)	2020-03-30	2021-10-07	Alnylam Pharmaceucticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
EP4127134A4 (en)	2020-04-01	2024-07-31	Alnylam Pharmaceuticals, Inc.	COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
EP4133078A1 (en)	2020-04-06	2023-02-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
EP4133077A1 (en)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
EP4133076A1 (en)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
KR20230008078A (ko)	2020-04-07	2023-01-13	알닐람 파마슈티칼스 인코포레이티드	Scn9a 발현을 사일런싱하기 위한 조성물 및 방법
BR112022021813A2 (pt)	2020-04-27	2023-01-17	Alnylam Pharmaceuticals Inc	Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
WO2021222549A1 (en)	2020-04-30	2021-11-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
EP4150077A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150088A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150089A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2023530234A (ja)	2020-06-05	2023-07-14	ザ・ブロード・インスティテュート・インコーポレイテッド	新生物を治療するための組成物および方法
EP4162050A1 (en)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
CN116075592A (zh)	2020-06-09	2023-05-05	阿尔尼拉姆医药品有限公司	用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
AR122722A1 (es)	2020-06-24	2022-09-28	Vir Biotechnology Inc	Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
MX2022016254A (es)	2020-06-25	2023-04-11	Synthorx Inc	Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr.
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
TW202228785A (zh)	2020-10-09	2022-08-01	美商欣爍克斯公司	使用il-2接合物及帕博利珠單抗(pembrolizumab)之免疫腫瘤學組合療法
AU2021356610A1 (en)	2020-10-09	2023-06-15	Synthorx, Inc.	Immuno oncology therapies with il-2 conjugates
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
CA3196205A1 (en)	2020-10-23	2022-04-28	Floyd E. Romesberg	Reverse transcription of polynucleotides comprising unnatural nucleotides
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
IL302709A (en)	2020-11-13	2023-07-01	Alnylam Pharmaceuticals Inc	Coagulation factor iRNA compositions (F5) and methods of using them
AU2021393417A1 (en)	2020-12-01	2023-06-29	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (en)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
US20240175020A1 (en)	2020-12-23	2024-05-30	Flagship Pioneering Innovations Vi, Llc	Compositions of modified trems and uses thereof
WO2022147223A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
AU2021411579A1 (en)	2020-12-31	2023-07-13	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202305131A (zh)	2021-02-12	2023-02-01	美商艾拉倫製藥股份有限公司	用於治療或預防超氧歧化酶１－（ＳＯＤ１－）相關的神經退化疾病的超氧歧化酶１（ＳＯＤ１）ｉＲＮＡ組成物及其使用方法
EP4291243A1 (en)	2021-02-12	2023-12-20	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
EP4298218A1 (en)	2021-02-26	2024-01-03	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
IL305442A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
EP4304640A1 (en)	2021-03-12	2024-01-17	Northwestern University	Antiviral vaccines using spherical nucleic acids
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
EP4314296A2 (en)	2021-03-29	2024-02-07	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
IL307298A (en)	2021-03-31	2023-11-01	Entrada Therapeutics Inc	Cell-penetrating circular peptides
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
CA3216106A1 (en)	2021-04-26	2022-11-03	Alnylam Pharmaceuticals, Inc.	Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (en)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
KR20240012425A (ko)	2021-05-10	2024-01-29	엔트라다 테라퓨틱스, 인크.	세포내 치료제를 위한 조성물 및 방법
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
US20250051780A1 (en)	2021-05-10	2025-02-13	Entrada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (en)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202313117A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
EP4347822A2 (en)	2021-06-04	2024-04-10	Alnylam Pharmaceuticals, Inc.	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
EP4351541A2 (en)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
KR20240038967A (ko)	2021-06-23	2024-03-26	엔트라다 테라퓨틱스, 인크.	Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
EP4363574A1 (en)	2021-06-29	2024-05-08	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
MX2024000981A (es)	2021-07-21	2024-02-12	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
AU2022316139A1 (en)	2021-07-23	2024-01-18	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
CN117795074A (zh)	2021-08-03	2024-03-29	阿尔尼拉姆医药品有限公司	转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
PE20241132A1 (es)	2021-08-04	2024-05-24	Alnylam Pharmaceuticals Inc	Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
JP2024534766A (ja)	2021-08-13	2024-09-26	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
EP4395790A2 (en)	2021-08-31	2024-07-10	Alnylam Pharmaceuticals, Inc.	Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
KR20240082344A (ko)	2021-09-01	2024-06-10	엔트라다 테라퓨틱스, 인크.	뒤센 근이영양증에서 엑손 44를 스키핑하기 위한 화합물 및 방법
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
WO2023056440A1 (en)	2021-10-01	2023-04-06	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
KR20240101590A9 (ko)	2021-10-15	2025-12-10	알닐람 파마슈티칼스 인코포레이티드	간외 전달 irna 조성물 및 이를 이용하는 방법
US20250352667A1 (en)	2021-10-22	2025-11-20	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4423273A1 (en)	2021-10-29	2024-09-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
WO2023092060A1 (en)	2021-11-18	2023-05-25	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (en)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
JP2025516680A (ja)	2022-05-13	2025-05-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	一本鎖ループオリゴヌクレオチド
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
JP2025532593A (ja)	2022-09-15	2025-10-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
CN120813691A (zh)	2023-02-09	2025-10-17	阿尔尼拉姆医药品有限公司	Reversir分子及其使用方法
EP4665865A1 (en)	2023-02-17	2025-12-24	Anjarium Biosciences AG	Methods of making dna molecules and compositions and uses thereof
WO2024196937A1 (en)	2023-03-20	2024-09-26	Synthorx, Inc.	Cancer therapy with il-2 peg conjugates
WO2024216155A1 (en)	2023-04-12	2024-10-17	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery of double-stranded rna agents
WO2024220930A2 (en)	2023-04-20	2024-10-24	Adarx Pharmaceuticals, Inc.	Mapt-modulating compositions and methods of use thereof
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en)	2023-04-24	2024-10-31	The Broad Institute, Inc.	Compositions and methods for modifying fertility
WO2024238385A2 (en)	2023-05-12	2024-11-21	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2024238396A1 (en)	2023-05-12	2024-11-21	Adarx Pharmaceuticals, Inc.	Nmda ligand conjugated compounds and uses thereof
CN121335980A (zh)	2023-05-26	2026-01-13	阿达尔克斯制药有限公司	Sod1调节组合物及其使用方法
AU2024313301A1 (en)	2023-06-20	2025-12-11	Adarx Pharmaceuticals, Inc.	Lrrk2-modulating compositions and methods of use thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
AU2024369609A1 (en)	2023-10-31	2025-12-11	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0117578A2 (en) *	1983-02-23	1984-09-05	Shionogi & Co., Ltd.	Azole-substituted alcohol derivatives
EP0251086A2 (en) *	1986-06-23	1988-01-07	The Du Pont Merck Pharmaceutical Company	Antifungal carbinols
EP0298332A1 (de) *	1987-07-10	1989-01-11	Bayer Ag	Hydroxyalkyl-azolyl-Derivate
WO1989005581A1 (en) *	1987-12-17	1989-06-29	E.I. Du Pont De Nemours And Company	Antifungal carbinols
EP0405267A1 (de) *	1989-06-30	1991-01-02	Bayer Ag	Hydroxyethyl-cyclopropyl-azolyl-Derivate
WO1991012000A1 (en) *	1990-02-13	1991-08-22	E.I. Du Pont De Nemours And Company	ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1978953A (en) *	1928-10-17	1934-10-30	Du Pont	Method of preparing an alkali metal perborate
DE548432C (de) *	1928-10-17	1932-04-12	Degussa	Herstellung eines Perborates
US3327684A (en) *	1963-03-11	1967-06-27	Fairchild Camera Instr Co	Masking apparatus for spray coating
FR2226460B1 (tr) *	1973-04-20	1976-12-17	Interox
JPS5315717B2 (tr) *	1973-12-20	1978-05-26
DE2652776A1 (de) *	1975-05-13	1978-05-24	Interox Chemicals Ltd	Verfahren zur herstellung von natriumpercarbonat
LU72575A1 (tr) *	1975-05-23	1977-02-10
DE2810379C3 (de) *	1978-03-10	1980-12-11	Degussa Ag, 6000 Frankfurt	Verfahren zur Herstellung von stabilisiertem Natriumpercarbonat
DE2712139C3 (de) *	1977-03-19	1982-05-19	Degussa Ag, 6000 Frankfurt	Natriumpercarbonat-Schichtpartikel
US4156039A (en) *	1976-11-11	1979-05-22	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler	Sodium percarbonate particles (A)
DE2651442C3 (de) *	1976-11-11	1979-11-15	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt	Natriumpercarbonat-Partikel
LU76548A1 (tr) *	1977-01-10	1978-09-18
DE2800760C2 (de) *	1978-01-09	1983-01-27	Degussa Ag, 6000 Frankfurt	Verfahren zur Herstellung von Natriumpercarbonat aus einer Sodalösung bzw. -suspension
GB1575792A (en) *	1978-01-10	1980-10-01	Interox	Peroxygen compounds
ES523135A0 (es) *	1982-06-10	1985-03-01	Kao Corp	Un procedimiento para la preparacion de percarborato sodico recubierto con un borato.
DE3321082C2 (de) *	1982-06-10	1996-08-22	Kao Corp	Bleich-Reinigungsmittel
DE3720277A1 (de) *	1987-06-19	1988-12-29	Degussa	Verfahren zur verminderung der neigung zum zusammenbacken von teilchenfoermigen aktivsauerstoffverbindungen
JP2636496B2 (ja) *	1990-11-21	1997-07-30	花王株式会社	安定な過炭酸ソーダ粒子及びその製造法

1993
- 1993-04-10 DE DE4311944A patent/DE4311944A1/de not_active Withdrawn
1994
- 1994-02-28 TW TW083101684A patent/TW265320B/zh active
- 1994-02-28 KR KR1019950704418A patent/KR100308473B1/ko not_active Expired - Fee Related
- 1994-02-28 CA CA002159991A patent/CA2159991A1/en not_active Abandoned
- 1994-02-28 WO PCT/EP1994/000576 patent/WO1994024044A1/de not_active Ceased
- 1994-02-28 EP EP94909085A patent/EP0693039B1/de not_active Expired - Lifetime
- 1994-02-28 FI FI954808A patent/FI954808A0/fi unknown
- 1994-02-28 CZ CZ952498A patent/CZ249895A3/cs unknown
- 1994-02-28 US US08/525,782 patent/US5658873A/en not_active Expired - Lifetime
- 1994-02-28 JP JP52265894A patent/JP3599737B2/ja not_active Expired - Fee Related
- 1994-02-28 AT AT94909085T patent/ATE156096T1/de active
- 1994-02-28 AU AU62078/94A patent/AU6207894A/en not_active Abandoned
- 1994-02-28 CN CN94191734A patent/CN1120832A/zh active Pending
- 1994-02-28 DE DE59403562T patent/DE59403562D1/de not_active Expired - Lifetime
- 1994-02-28 ES ES94909085T patent/ES2106515T3/es not_active Expired - Lifetime
- 1994-02-28 PL PL94311035A patent/PL173925B1/pl unknown
- 1994-04-04 TR TR00294/94A patent/TR27402A/tr unknown
- 1994-04-07 SI SI9400166A patent/SI9400166A/sl unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0117578A2 (en) *	1983-02-23	1984-09-05	Shionogi & Co., Ltd.	Azole-substituted alcohol derivatives
EP0251086A2 (en) *	1986-06-23	1988-01-07	The Du Pont Merck Pharmaceutical Company	Antifungal carbinols
EP0298332A1 (de) *	1987-07-10	1989-01-11	Bayer Ag	Hydroxyalkyl-azolyl-Derivate
WO1989005581A1 (en) *	1987-12-17	1989-06-29	E.I. Du Pont De Nemours And Company	Antifungal carbinols
EP0405267A1 (de) *	1989-06-30	1991-01-02	Bayer Ag	Hydroxyethyl-cyclopropyl-azolyl-Derivate
WO1991012000A1 (en) *	1990-02-13	1991-08-22	E.I. Du Pont De Nemours And Company	ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OGATA M. ET AL.: "Synthesis and oral antifungal activity of novel azolylpropanolones and related compounds", JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, no. 6, June 1987 (1987-06-01), pages 1054 - 1068 *

Also Published As

Publication number	Publication date
FI954808A7 (fi)	1995-10-09
DE4311944A1 (de)	1994-10-13
KR100308473B1 (ko)	2002-07-02
CN1120832A (zh)	1996-04-17
CZ249895A3 (en)	1996-04-17
FI954808L (fi)	1995-10-09
JPH08508707A (ja)	1996-09-17
EP0693039A1 (de)	1996-01-24
FI954808A0 (fi)	1995-10-09
AU6207894A (en)	1994-11-08
ATE156096T1 (de)	1997-08-15
PL311035A1 (en)	1996-01-22
CA2159991A1 (en)	1994-10-27
JP3599737B2 (ja)	2004-12-08
US5658873A (en)	1997-08-19
TW265320B (tr)	1995-12-11
ES2106515T3 (es)	1997-11-01
EP0693039B1 (de)	1997-07-30
PL173925B1 (pl)	1998-05-29
WO1994024044A1 (de)	1994-10-27
DE59403562D1 (de)	1997-09-04
SI9400166A (en)	1994-12-31
KR960701801A (ko)	1996-03-28

Publication	Publication Date	Title
TR27402A (tr)	1995-02-28	Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.
US4347149A (en)	1982-08-31	Aqueous bleach compositions
US4497725A (en)	1985-02-05	Aqueous bleach compositions
DE2965289D1 (en)	1983-06-01	Pourable scouring cleanser compositions
PL310951A1 (en)	1996-01-08	Stable, bifunctional phosphate-, metasilicate- and polymer-free low-alkaline cleaning agent tablets for machine dish-washing and method of making such tablets
GB1513305A (en)	1978-06-07	Bleaching compositions and method of bleaching
NO900341L (no)	1990-07-26	Toeyvaskemiddelblanding.
EP0813586B1 (en)	1999-07-28	Mold remover product
ATE164624T1 (de)	1998-04-15	Bleichmittel
US2362401A (en)	1944-11-07	Detergent compositions
CA2029262A1 (en)	1991-05-10	Bleaching composition
AU668900B2 (en)	1996-05-23	Alkaline hydrogen peroxide composition
ES374141A1 (es)	1972-03-01	Procedimiento para la preparacion de medios de fregado pul-verulentos.
ATE16609T1 (de)	1985-12-15	Waessriges bleichmittel mit reinigungswirkung.
US5914305A (en)	1999-06-22	Peroxynitrite based bleaching systems
AU698072B2 (en)	1998-10-22	Lacto/peroxide bleaching solution, a bleaching system for forming the same and method of preparing and using the same
CA2204507C (en)	2002-02-19	Thickened bleaching compositions, method of use and process for making them
JP2000510179A (ja)	2000-08-08	シアノピリジンｎ―酸化物過酸化物漂白活性化剤
EP0157483A1 (en)	1985-10-09	Peroxide activation
ES439370A1 (es)	1977-02-16	Un procedimiento para preparar perhidratos de tano-tetracar-boxilato.
NO911223L (no)	1991-10-01	Fremgangsmaate for fremstilling og/eller opprettholdelse av alkaliske blekebad og hydrogenperoksidopploesninger for anvendelse deri
MXPA97006869A (en)	1998-11-09	Removed product of m
ATE300600T1 (de)	2005-08-15	Bleichmittel enthaltende reinigungszusammensetzung
TH16436B (th)	2004-03-17	สารผสมสารทำความสะอาดที่ใช้ฟอกจาง
TH2031A (th)	1984-12-03	ส่วนประกอบสารฟอกสีในการฟอกล้าง